facebook
AOI Online Chat

Dr Amit Kumar Dhiman

  • Dr. Amit Kumar Dhiman completed his MBBS from Dayanand Medical College and Hospital, Ludhiana, India – Nov. 1998.
  • He did his MD (Internal Medicine) from Dayanand Medical College and Hospital, Ludhiana, India – Dec. 2004.
  • He completed Professional Diploma In Clinical Research (PDCR) from Catalyst Clinical Services Pvt. Ltd. New Delhi – Jun. 2008.
  • He became a Diplomate in National Board (DNB) in Medical Oncology from Rajiv Gandhi Cancer Institute & Research Centre, New Delhi, Feb. 2010.

Membership

  • European Society of Medical Oncology (ESMO) from 2014.
  • Dec. 2013 to Mar. 2017 – Head of Medical Oncology & Assistant Professor Medical Oncology in Dayanand Medical College and Hospital, Ludhiana.
  • May 2012 to Nov. 2013 – Assistant Professor Medical Oncology in Dayanand Medical College, Ludhiana.
  • Oct. 2010 to May 2012 – Associate Consultant Medical Oncology – S P S Apollo Hospital, Ludhiana, India.
  • May 2010 to Sept. 2010 – Associate Consultant in Medical Oncology – Medanta Medicity, Medanta Cancer Institute, Gurgaon, India.

Special Interests:

  • Dr Amit looks after all types of cancer – malignant & benign haematological disorders.
  • His special interest is in breast, ovarian cancer, multiple myeloma, lymphoma, MDS and leukemia’s.

Teaching Experience:

  • Dr Amit is the faculty for undergraduates covering all aspects of medicine. He took classes for medical undergraduate students and trainee technologist in medicine and medical oncology.
  • During his DNB training, He was taking practical classes of junior students of medical oncology.
  • As Assistant Professor in the Department of Medicine – Unit of Medical Oncology, He takes classes related to Oncology for under graduates & post graduate students with aim to teach presentation, diagnosis & screening of cancers with academic classes, clinical classes, bed side demonstrations and tumour board meetings.
  • Registered with Delhi Medical Council: DMC No. 32748
  • Registered with Punjab Medical Council: PMC No. 31448

As Principal Investigator (On going)

  • A prospective, randomized, multi-center study to compare the safety, tolerability and efficacy of Bevacizumab (Zydus Cadila) With Bevacizumab (Avastin) in Non-Small Cell Lung Cancer (NSCLC).
  • A randomized, double-blinded, two-treatment, single dose, two-period, cross-over, multi-center comparative bioequivalence study of Mercaptopurine in patients suffering from acute lymphoblastic leukemia under fasting condition.
  • Reditux registry to compare effectiveness, safety & resource utilization of Reditux vs. the reference medical product to treat Diffuse Large Cell Lymphoma & Chronic Lymphocytic Leukemia in routine clinical practice.
  • Multicenter randomized double blind phase III clinical trial comparing safety and efficacy of BCD022 (CJSC BIOCAD, Russia) used with paclitaxel to Herceptin Switzerland used with F. Hoffmann paclitaxel in the first– La Roche Ltd, line treatment of HER2 Test Drug — positive metastatic breast cancer patients.

As Sub Investigator

  • Phase II study of a new drug combination versus cisplatin locally advanced metastatic gall bladder cancer.
  • A randomized phase III study of a new drug combination versus paclitaxel in metastatic breast cancer-a multinational multi institutional study. A US FDA registration trial.
  • A phase III trial of a new agent plus gemcitabine and cisplatin versus gemcitabine and cisplatin in patients with advanced, previously untreated non-small cell lung cancer a multinational multi-institutional study. A US FDA registration trial.
  • An open label single arm phase 2 study of a new agent in patients with advanced non-small cell lung cancer who have had prior chemotherapy.
  • A randomized, controlled open label study to evaluate the efficacy and safety of trastuzumab in combination with oral aromatase inhibitor anastrozde compared with anastrozole alone as first and second line treatment administered to post-menopausal hormone receptor positive (ER positive and or PR positive) patients with her 2 over expressing metastatic breast cancer.
  • As un-blinded pharmacist in a multi-centre double blind randomized, comparative, randomized study to evaluate the efficacy and safety of a new agent versus liposomal amphotericin b (ambisome) in the treatment of invasive candiasis and candidemia a phase III study.
  • A randomized, double blind, placebo controlled phase 2 study of new agent monotherapy in patient with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have failed 1st or 2nd line chemotherapy.
  • An open label phase 2 study of new agent monotherapy in patients with advanced or metastatic renal cell carcinoma (RCC).
  • A phase III study of new agent combined with epirubicin & cyclophosphamide versus epirubicin & cyclophosphamide alone as first line treatment in metastatic/recurrent breast cancer. a multicentre study of new formulation in locally advanced & metastatic breast cancer.
  • A phase III, randomized, double-blind, comparative study of new agent versus caspofungin as antifungal treatment in patients with invasive candidiasis or candidemia.
  • An open- label randomized phase II study of two different dosing regimens of capecitabine in combination with intravenous docetaxel (q3w) in patients with locally advanced and/or metastatic breast cancer. A roche sample repository research project no16853rg for use in conjunction with protocol n016853d.
  • A randomized, controlled, open-labeled, multi-center, comparison of thalidomide versus high dose dexamethasone for the treatment of relapsed, refractory multiple myeloma.
  • A multi-center, open label, parallel group, randomized, phase IIb clinical trial to evaluate the safety and efficacy of cofactor tm and 5-fu versus leucovorin and 5-fu in subjects with metastatic colorectal carcinoma.
  • A “international, randomized, open-label, phase 3 trial of gemcitabine/cisplatin plus pf-3512676 versus gemcitabine/cisplatin alone as first-line treatment of patients with advanced non-small cell lung cancer.
  • A multicenter study of cremophor free, polymeric nanoparticle formulation of paclitaxel (do/ndr/02) in locally advanced and metastatic breast cancer
  • A randomized phase II study of biweekly gemcitabine – paclitaxel, biweekly gemcitabine-carboplatin and biweekly gemcitabine – cisplatin as first line treatment in metastatic breast cancer after anthracycline failure
  • A randomized phase 3 trial of alimta (pemetrexed) and carboplatin versus etoposide and carboplatin in extensive- stage small cell lung cancer
  • A randomized, double-blind, multicenter study of denosumab compared with zoledronic acid (zometa) in the treatment of bone metastases in men with hormone-refractory prostate cancer
  • A phase 2, randomized ,double – masked , placebo -controlled study to evaluate the efficacy of snx- 1012 in reducing the duration and severity of ulcerative oral mucositis in patienta receving cytotoxic chemotherapy for the breast or lung cancer.
  • A randomised , multicentre therapeutic confirmatory study to evaluate the efficacy and safety of proxinium tm plus best supportive care versus best supportive care alone in patients with advanced squamous cell carcinoma of the head and neck who have receiveed atleast one anti cancer treatment regimen for the advanced disease.
  • An open label randomised , phase 3 , study of cmc – 544 administered combination with rituximab in subjects with relapsed or refractory follicular b – cell non –hodgkin,s lymphoma compared to a defined investigator,s chioce.
  • An open – label ,dose finding , prospective , multi- centre , randomisation , parallel group study to assess the efficacy and safety of three different dose levels of avi -01 (g-csf) compared with a standared dose of neupogen in breast cancer patients at high (>20%) risk for chemotherapy – induced severe neutropenia.
  • A phase II biomarker identification trial for new agent in patient with advance pancreatic carcinoma.
  • A randomized, multi-center, open label study to evaluate the efficacy and safety of new agent as compared to grafeel in the prophylaxis of severe neutropenia in cancer patients receiving cytotoxic chemotherapy

Research papers presented at conferences (International/National/ Regional)

  • Experience with Gefitinib in women with lung cancer: Asia pacific lung cancer conference/ASCO/UICC/ESMO. 2008, Hyderabad, India.
  • Gemcitabine and cisplatin as adjunctive treatment in operable NSCLC: Asia pacific lung cancer conference/ASCO/UICC/ESMO. 2008, Hyderabad, India.
  • To analyze the efficacy, tolerability, toxicity profile of adjuvant TAC regimen in breast cancer. ISMPO conference, 2008, Chennai, India.

International Poster Presentation

  • Efficacy of FOLFOX 4 in Carcinoma Gall bladder – experience from centre in Northern India. – accepted for poster presentation in ESMO Conference: 11th World Congress on Gastrointestinal Cancer at CCIB, Barcelona. 24th to 27th June 2009.
  • J S Sandhu, A Dhiman, R Mahajan, P Sandhu. Outcome of paraquet poisoning- a five year study. Indian J. of Nephrology. Apr-Jun 2003; 13:64-68.
  • Amit Dhiman, Lalit Bansal, Jagdev Sekhon, R. Ranga Rao, Amarinder Sekhon and Neeraj Prakash multiple myeloma presenting with hepatic involvement; Indian Journal of Medical & Paediatric oncology 2007, vol. 28 no 3,41-43.
  • R. Rangaraju, K Anil, J Sharma, A Anand, A Dewan, S Rawat, S Batra, A Dhiman. Cetuximab In Weekly Multiagent Chemotherapy In Recurrent Head And Neck Cancer. Abstract In Asco 2008 Meeting, Head & Neck Meeting.
  • R. Ranga Rao, Konnpal Anil, Lalit Bansal, Amit Dhiman, Sameer Khatri, Shneh Rawat And Ajay Dewansurvival Benefit And Efficacy Of Geftinib In Recurrent Head And Neck Cancer. Indian Journal Of Medical & Paediatric Oncology Vol. 28 No (3),5-10. 2007
  • JS Sandhu, A Dhiman, Bs Aulakh, P Sandhu, K Saggar, N Sood, Ns Khaira. Post -Transplant Malignancies – 8 Cases Observed In A Single Center. Indian J Nephrology 2005;15: 235-238
  • J S Sekhon, Amit Dhiman. Tuberculasis And Lung Cancer: Tuberculosis.( Book) Jay Pee publisher.
  • Himesh gupta, Amit Dhiman, Gauri Kapoor. ‘Germ Cell Tumors’ Chapter in Proposed Text book of book ‘Pediatric Hematology, Oncology & Immunology’. Indian Association of Pediatrics.
  • TVSVGK Tilak, Amit Dhiman. ‘New Diagnostics and screening methods for Cancer’. Textbook of Association of Physician of India year 2016, Chapter 40.
  • Textbook of Association of Physician of India year 2016.
  • Member of editorial board of Journal of “ Asian Journal Of Oncology”